| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 16,613 | 20,575 |
| Change in fair value of warrant liability | -26,656 | -26,659 |
| Depreciation and amortization | 17 | 2 |
| Stock-based compensation | 401 | 266 |
| Receivables | 226 | -442 |
| Prepaid expenses and other current assets | -634 | -882 |
| Accounts payable | -3,081 | -3,605 |
| Accrued expenses and other current liabilities | -339 | -528 |
| Deferred revenue | -2,790 | -2,791 |
| Net cash used in operating activities | -15,427 | -11,416 |
| Cash paid for acquisition, net of cash acquired | 2,585 | - |
| Net cash used in investing activities | -2,585 | - |
| Proceeds from sale of common stock pursuant to the atm | 3,495 | 3,379 |
| Payment of offering costs | 465 | 287 |
| Proceeds from exercised prefunded warrants | 16 | 16 |
| Net cash provided by financing activities | 3,046 | 3,108 |
| Effect of foreign currency translation on cash | 48 | 51 |
| Net decrease in cash and cash equivalents | -14,918 | -8,257 |
| Cash and cash equivalents at beginning of period | 21,338 | - |
| Cash and cash equivalents at end of period | 6,420 | - |
Traws Pharma, Inc. (TRAW)
Traws Pharma, Inc. (TRAW)